Recent publications on Cancer
Lee FC, Harris W, Cheng HH, Shenoi J, Zhao S, Wang J, Champion T, Izard J, Gore JL, Porter M, Wright JL. Pathologic response rates of gemcitabine/cisplatin versus methotrexate/vinblastine/adriamycin/cisplatin neoadjuvant chemotherapy for muscle invasive urothelial bladder cancer. Adv Urol. 2013;2013:317190. doi: 10.1155/2013/317190. Epub 2013 Dec 8. PubMed
Rutter CM, Johnson EA, Feuer EJ, Knudsen AB, Kuntz KM, Schrag D. Secular trends in colon and rectal cancer relative survival. J Natl Cancer Inst. 2013 Dec 4;105(23):1806-13. doi: 10.1093/jnci/djt299. Epub Oct 30. PubMed
Onitilo AA, Onesti JK, Single RM, Engel JM, James TA, Aiello Bowles EJ, Feigelson HS, Barney T, McCahill LE. Utilization of neoadjuvant chemotherapy varies in the treatment of women with invasive breast cancer. PLoS One. 2013 Dec 20;8(12):e84535. doi: 10.1371/journal.pone.0084535. PubMed
Taira AV, Merrick GS, Butler WM, Galbreath RW, Fiano R, Wallner KE, Adamovich E. Time to failure after definitive therapy for prostate cancer: implications for importance of aggressive local treatment. J Contemp Brachytherapy. 2013 Dec;5(4):215-21. doi: 10.5114/jcb.2013.39210. Epub 2013 Dec 3. PubMed
Moyer VA, LeFevre ML, Siu AL, Peters JJ, Baumann JJ, Bibbins-Domingo K, Curry SJ, Ebell M, Flores G, Garcia FA, Cantu AG, Grossman DC, Herzstein J, Nicholson WK, Owens DK, Phillips WR, Pignone MP. Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013 Nov 19;159(10):698-708. doi: 10.7326/0003-4819-159-10-201311190-00717. PubMed
Roman M, Hubbard RA, Sebuodegard S, Miglioretti DL, Castells X, Hofvind S. The cumulative risk of false-positive results in the Norwegian Breast Cancer Screening Program: updated results. Cancer. 2013 Nov 15;119(22):3952-8. doi: 10.1002/cncr.28320. Epub 2013 Aug 20. PubMed
O'Meara ES, Zhu W, Hubbard RA, Braithwaite D, Kerlikowske K, Dittus KL, Geller B, Wernli KJ, Miglioretti DL. Mammographic screening interval in relation to tumor characteristics and false-positive risk by race/ethnicity and age. Cancer. 2013 Nov 15;119(22):3959-67. doi: 10.1002/cncr.28310. Epub 2013 Aug 26. PubMed
Chubak J, Bogart A, Fuller S, Laing SS, Green BB. Uptake and positive predictive value of fecal occult blood tests: a randomized controlled trial. Prev Med. 2013 Nov;57(5):671-8. doi: 10.1016/j.ypmed.2013.08.032. Epub 2013 Sep 9. PubMed
Onitilo AA, Engel JM, James TA, Aiello Bowles EJ, McCahill LE, Feigelson HS. Reply to: Should initial mastectomy rates increase? J Am Coll Surg. 2013 Nov;217(5):960-2. doi: 10.1016/j.jamcollsurg.2013.07.396. PubMed
Mazor KM, Beard RL, Alexander GL, Arora NK, Firneno C, Gaglio B, Greene SM, Lemay CA, Robinson BE, Roblin DW, Walsh K, Street RL Jr, Gallagher TH. Patients' and family members' views on patient-centered communication during cancer care. Psychooncology. 2013 Nov;22(11):2487-95. doi: 10.1002/pon.3317. Epub 2013 Jun 18. PubMed
Dittus K, Geller B, Weaver DL, Kerlikowske K, Zhu W, Hubbard R, Braithwaite D, O'Meara ES, Miglioretti DL. Impact of mammography screening interval on breast cancer diagnosis by menopausal status and BMI. J Gen Intern Med. 2013 Nov;28(11):1454-62. doi:10.1007/s11606-013-2507-0. Epub 2013 Jun 13. PubMed
Carney PA, Geller BM, Bogart A, Sickles EA, Smith RA, Buist DS, Kerlikowske K, Onega TL, Miglioretti DL, Rosenberg R, Yankaskas BC. Feasibility and acceptability of conducting a randomized clinical trial designed to improve interpretation of screening mammography. Acad Radiol. 2013 Nov;20(11):1389-98. doi: 10.1016/j.acra.2013.08.017. PubMed
Buist DS, Bosco JL, Silliman RA, Gold HT, Field T, Yood MU, Quinn VP, Prout M, Lash TL. Long-term surveillance mammography and mortality in older women with a history of early stage invasive breast cancer. Breast Cancer Res Treat. 2013 Nov;142(1):153-63. doi: 10.1007/s10549-013-2720-x. Epub 2013 Oct 11. PubMed
Chubak J, Boudreau DM, Wirtz HS, McKnight B, Weiss NS. Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst. 2013 Oct 2;105(19):1456-62.doi:10.1093/jnci/djt211. Epub 2013 Aug 12. Review. PubMed
Farhat GN, Parimi N, Chlebowski RT, Manson JE, Anderson G, Huang AJ, Vittinghoff E, Lee JS, LaCroix AZ, Cauley JA, Jackson R, Grady D, Lane DS, Phillips L, Simon MS, Cummings SR. Sex hormone levels and risk of breast cancer with estrogen plus progestin. J Natl Cancer Inst. 2013 Oct 2;105(19):1496-503. doi: 10.1093/jnci/djt243. Epub 2013 Sep 16. PubMed
Rustagi AS, Kamineni A, Weiss NS. Point: cervical cancer screening guidelines should consider observational data on screening efficacy in older women. Am J Epidemiol. 2013 Oct 1;178(7):1020-2. doi: 10.1093/aje/kwt167. Epub 2013 Aug 21. PubMed
Owens CL, Peterson D, Kamineni A, Buist DS, Weinmann S, Ross TR, Williams AE, Stark A, Adams KF, Field TS. Effects of transitioning from conventional methods to liquid-based methods on unsatisfactory Papanicolaou tests: Results from a multicenter US study. Cancer Cytopathol. 2013 Oct;121(10):568-75. doi:10.1002/cncy.21309. Epub 2013 May 8. PubMed
Loggers ET, Maciejewski PK, Jimenez R, Nilsson M, Paulk E, Stieglitz H, Prigerson HG. Predictors of intensive end-of-life and hospice care in Latino and white advanced cancer patients. J Palliat Med. 2013 Oct;16(10):1249-54. doi: 10.1089/jpm.2013.0164. Epub 2013 Sep 20. PubMed
Green DM, Lange JM, Qu A, Peterson SM, Kalapurakal JA, Stokes DC, GrigorievYA, Takashima JR, Norkool P, Friedman DL, Breslow NE. Pulmonary disease after treatment for Wilms tumor: a report from the National Wilms Tumor Long-term Follow-up study. Pediatr Blood Cancer. 2013 Oct;60(10):1721-6. doi: 10.1002/pbc.24626. Epub 2013 Jun 14. PubMed
Li W, Ray RM, Thomas DB, Yost M, Davis S, Breslow N, Gao DL, Fitzgibbons ED, Camp JE, Wong E, Wernli KJ, Checkoway H. Occupational exposure to magnetic fields and breast cancer among women textile workers in Shanghai, China. Am J Epidemiol. 2013 Oct 1;178(7):1038-45. doi: 10.1093/aje/kwt161. Epub 2013 Sep 15. PubMed
